Literature DB >> 24533473

The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.

Antje Dittmann1, Thilo Werner, Chun-Wa Chung, Mikhail M Savitski, Maria Fälth Savitski, Paola Grandi, Carsten Hopf, Matthew Lindon, Gitte Neubauer, Rabinder K Prinjha, Marcus Bantscheff, Gerard Drewes.   

Abstract

A commonly used small-molecule probe in cell-signaling research is the phosphoinositide 3-kinase inhibitor LY294002. Quantitative chemoproteomic profiling shows that LY294002 and LY303511, a close analogue devoid of PI3K activity, inhibit the BET bromodomain proteins BRD2, BRD3, and BRD4 that comprise a family of targets structurally unrelated to PI3K. Both compounds competitively inhibit acetyl-lysine binding of the first but not the second bromodomain of BET proteins in cell extracts. X-ray crystallography shows that the chromen-4-one scaffold represents a new bromodomain pharmacophore and establishes LY294002 as a dual kinase and BET-bromodomain inhibitor, whereas LY303511 exhibits anti-inflammatory and antiproliferative effects similar to the recently discovered BET inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24533473     DOI: 10.1021/cb400789e

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  41 in total

Review 1.  The bromodomain: from epigenome reader to druggable target.

Authors:  Roberto Sanchez; Jamel Meslamani; Ming-Ming Zhou
Journal:  Biochim Biophys Acta       Date:  2014-03-28

2.  Transcriptional Elongation of HSV Immediate Early Genes by the Super Elongation Complex Drives Lytic Infection and Reactivation from Latency.

Authors:  Roberto Alfonso-Dunn; Anne-Marie W Turner; Pierre M Jean Beltran; Jesse H Arbuckle; Hanna G Budayeva; Ileana M Cristea; Thomas M Kristie
Journal:  Cell Host Microbe       Date:  2017-04-12       Impact factor: 21.023

3.  Co-inhibition of BET proteins and PI3Kα triggers mitochondrial apoptosis in rhabdomyosarcoma cells.

Authors:  Cathinka Boedicker; Michelle Hussong; Christina Grimm; Nadezda Dolgikh; Michael T Meister; Julius C Enßle; Marek Wanior; Stefan Knapp; Michal R Schweiger; Simone Fulda
Journal:  Oncogene       Date:  2020-03-11       Impact factor: 9.867

Review 4.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

5.  Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.

Authors:  Forest H Andrews; Alok R Singh; Shweta Joshi; Cassandra A Smith; Guillermo A Morales; Joseph R Garlich; Donald L Durden; Tatiana G Kutateladze
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

Review 6.  Epigenetic drug discovery: breaking through the immune barrier.

Authors:  David F Tough; Paul P Tak; Alexander Tarakhovsky; Rab K Prinjha
Journal:  Nat Rev Drug Discov       Date:  2016-10-21       Impact factor: 84.694

Review 7.  BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.

Authors:  Dequina A Nicholas; Guillaume Andrieu; Katherine J Strissel; Barbara S Nikolajczyk; Gerald V Denis
Journal:  Cell Mol Life Sci       Date:  2016-08-04       Impact factor: 9.261

Review 8.  Targeting Cancer Cells with BET Bromodomain Inhibitors.

Authors:  Yali Xu; Christopher R Vakoc
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

9.  Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

Authors:  Alok R Singh; Shweta Joshi; Adam M Burgoyne; Jason K Sicklick; Sadakatsu Ikeda; Yuko Kono; Joseph R Garlich; Guillermo A Morales; Donald L Durden
Journal:  Mol Cancer Ther       Date:  2016-08-05       Impact factor: 6.261

10.  The Bromodomain: A New Target in Emerging Epigenetic Medicine.

Authors:  Steven G Smith; Ming-Ming Zhou
Journal:  ACS Chem Biol       Date:  2015-12-03       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.